Addressing the need for more therapeutic options in neuroendocrine prostate cancer

Jayson Kemble, Eugene D. Kwon, R. Jeffrey Karnes

Research output: Contribution to journalReview articlepeer-review


Introduction: Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer frequently seen after prolonged treatment of castration resistant prostate cancer (CRPC). NEPC has become increasingly prevalent over the last 20 years, with a poor prognosis caused by a late diagnosis and limited treatment options. Recent advances in PET/CT imaging and targeted radioimmunotherapy are promising, but more research into additional treatment options is needed. Areas covered: The aim of this review is to analyze the current imaging and treatment options for NEPC, and to highlight future potential treatment strategies. A Pubmed search for ‘Neuroendocrine Prostate Cancer’ was performed and relevant articles were reviewed. Expert opinion: The recent FDA approval and success of 177 PSMA Lutetium in CRPC is promising, as 177 Lutetium could potentially be paired with a NEPC specific biomarker for targeted therapy. Recent laboratory studies pairing DLL3, which is overexpressed in NEPC, with 177 Lutetium and new PET agents have showed good efficacy in identifying and treating NEPC. The success of future development of NEPC therapies may depend on the availability of 177 Lutetium, as current supplies are limited. Further research into additional imaging and treatment options for NEPC is warranted.

Original languageEnglish (US)
Pages (from-to)177-185
Number of pages9
JournalExpert review of anticancer therapy
Issue number2
StatePublished - 2023


  • 177 lutetium
  • Castration resistant prostate cancer
  • PET/CT
  • chemotherapy
  • neuroendocrine prostate cancer
  • platinum

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Addressing the need for more therapeutic options in neuroendocrine prostate cancer'. Together they form a unique fingerprint.

Cite this